Summary
The nucleotide substitution G1896A on the precore (pc) region has been implicated in virological and serological responses during treatment in hepatitis B virus (HBV)-infected patients. Whether this mutation affects the therapeutic course of HIV-HBV co-infected patients, especially from Western Africa, is unknown. In this prospective cohort study, 86 antiretroviral (ARV)-naïve HIV-HBV co-infected patients from Côte d'Ivoire, initiating ARV-treatment containing lamivudine (n = 53) or tenofovir (n = 33), had available baseline pc sequences. Association of the pcG1896A mutation with time to undetectable HBV-DNA, hepatitis B "e" antigen (HBeAg) seroclearance (in HBeAg-positive patients), and hepatitis B surface antigen (HBsAg) seroclearance was evaluated using Cox proportional hazards regression. At ARV-initiation, median HBV-DNA was 6.04 log 10 copies/mL (IQR = 3.70-7.93) with 97.7% harbouring HBV genotype E. Baseline pcG1896A mutation was identified in 51 (59.3%) patients, who were more commonly HBeAg-negative (P < .001) and had basal core promotor
| INTRODUC TI ON
In sub-Saharan Africa (SSA), it is estimated that approximately 10% of HIV-infected patients have chronic hepatitis B virus (HBV) infection.
1 HIV-HBV co-infection is known to increase the risk of severe liver disease and accelerate progression to liver-related death compared to either infection individually. 2, 3 Circulating HBV is a strong contributor of the increased risk in both liver-related and overall mortality 4, 5 ; hence, the importance of reducing serum HBV-DNA viral loads through effective antiviral therapy. 6, 7 There are, however, certain virological factors of the HBV genome that might impact response during therapy with an anti-HBV nucleoside/nucleotide analogue (NA). For example, patients harbouring the precore (pc) G1896A mutation are less likely to achieve lower HBV-DNA viral loads during treatment with lamivudine (LAM). 8 Pc mutant variants have been shown in vitro to increase replication yields of LAM-resistant strains, which are normally deficient in replicative capacity 9 and have been clinically associated with faster development of LAM resistance. 10 Importantly, the presence of pc mutations, even when existing as a minority quasispecies, hampers hepatitis B surface antigen (HBsAg) loss during treatment with the potent NA tenofovir (TDF). 11 The pcG1896A mutation would then appear to impose serious consequences on the therapeutic course of NA-treated patients.
Within the continent, data on the prevalence of pc mutations in both HBV mono-infected and HIV-HBV co-infected patients are certainly available. [12] [13] [14] [15] [16] However, their implications with respect to virological and serological response during anti-HBV NA therapy remain to be elucidated. In the study herein, we used unique data from a cohort of antiretroviral treatment (ART)-naïve HIV-HBV co-infected patients from Côte d'Ivoire initiating treatment with an anti-HBV containing regimen. We first evaluated the distribution of mutations observed on the basal core promoter (BCP) and pc regions before treatment initiation, while examining risk factors of harbouring the pcG1896A mutation. We then aimed to determine the effect of harbouring this mutation on virological and serological response during LAM-or TDF-containing ART. LAM and/or TDF at inclusion or any time during participation in the trial (Data S1). We defined the "baseline" visit at ART-initiation and "follow-up" visits at each yearly visit thereafter until the date A1762T/G1764A mutations (P < .001). Patients were followed for a median 36 months (IQR = 24-36). Cumulative proportion of undetectable HBV-DNA was significantly higher in patients with baseline mutation (pcG1896A = 86.6% vs no pcG1896A = 66.9%, P = .04), but not after adjusting for baseline HBV-DNA levels and anti-HBV agent (P = .2). No difference in cumulative proportion of HBeAg seroclearance was observed between mutation groups (pcG1896A = 57.1% vs no pcG1896A = 54.3%, P = .7).
| MATERIAL S AND ME THODS

| Study design and visits
Significantly higher cumulative proportion of HBsAg seroclearance was observed in patients without this mutation (pcG1896A = 0% vs no pcG1896A = 36.9%, P < .001), even after adjusting for baseline HBsAg quantification and anti-HBV agent (P < .001).
In conclusion, lacking the pcG1896A mutation before ARV initiation appeared to increase HBsAg seroclearance rates during treatment. The therapeutic implications of this mutation need further exploration in this setting.
K E Y W O R D S
antiviral treatment, basal core promoter, genetic variability, immunosuppression, precore of last follow-up (with available frozen sample), study termination, permanent treatment discontinuation or treatment switch. In the Temprano study, if the last follow-up visit was not on the yearly interval, the closest 6-month visit was used instead. 
| HBV-related parameters
| Detection of HBV mutations on viral genome sequences
Genotypic analysis was performed at baseline for all patients with an HBV-DNA viral load >1000 copies/mL. 17 Nucleotide (nt) sequences from the BCP and pc regions were examined by direct sequencing after nested-PCR amplification of the preC/C gene (nt 1743-2362).
Individual sequences were aligned using the ClustalW full multiple alignment program with 1000 bootstraps in BioEdit (v7.0.5.3, Carlsbad, CA, USA) and were compared to a consensus sequence from 454 genotype E and 500 genotype A preC/C nucleotide sequences retrieved from the HBVdb.
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Amino acid sequences of the pol and S-genes were also examined after PCR amplification of the reverse transcriptase (rt) and surface antigen (s) encoding regions (between rt107-rt385 and s99-s226, respectively). Mutant variants were detected using similar methods as described above. 
| Phylogenetic analysis
Hepatitis B virus genotypes were determined via phylogenetic analysis conducted on aligned sequences of the pc region (nt 1814-2452), which were compared to several referent sequences of HBV genotypes A-H (GenBank accession numbers listed in Table S1 ). The neighbour-joining method was employed with 1000 bootstrap replications using a Kimura-2 parameter substitution model that included transitions and transversions (d). A discrete gamma model with mean equal to one was also used to incorporate rate variation among sites.
The resulting phylogenetic tree was constructed using MEGA6 software 22 and is provided in Figure S1 .
| Statistical analysis
The distribution of specific mutations of the preC/C gene 13 at baseline was described. We chose to focus further analysis on the pcG1896A mutation due to its strong association with virological and serological responses. 23 Determinants of harbouring this mutation at inclusion were examined using logistic regression. Demographic, treatment and clinical characteristics related to HIV and HBV infection with a P ≤ .1 in univariable analysis were retained and used to create a predictive, multivariable model. A backwards-stepwise selection process was then performed, removing any co-variable greater than this P-value threshold.
We then assessed the effect of harbouring the pcG1896A mutation at inclusion on virological and serological parameters during treatment. The cumulative probability of time until undetectable HBV, time until HBeAg seroclearance (for patients with positive HBeAg at baseline) and time until HBsAg seroclearance was calculated using
Kaplan-Meier curves. Survivor functions were stratified on mutation groups and compared using the log-rank test. Cox proportional hazards regression was also used to compare rates of these events, both unadjusted and adjusted for baseline quantified parameter (HBV-DNA, qHBeAg or qHBsAg) and anti-HBV treatment (LAM vs TDF).
Additionally, qHBsAg levels were summarized for each study visit. Changes in antigen levels from baseline were modelled using a mixed-effect linear regression with a random intercept to account for between-patient variability. The model included time and mutation group as independent variables along with the interaction between the two, which was tested in order to determine differences in overall on-treatment antigen decline between mutation groups.
All analyses were performed using STATA (v12.1, College Station, TX, USA). All statistical tests were two-sided, and a P-value of <.05 was considered significant.
| RE SULTS
| Description of the study population
Among the 259 HBsAg-positive patients enrolled in both trials, 173
were not included in analysis for the following reasons: did not have confirmed HBsAg-positive serology (n = 31) or had suspected acute HBV infection (n = 1), never initiated ART (n = 30), had only one follow-up visit (n = 16), discontinued ART <6 months due to pregnancy (n = 3) or adverse event (n = 2), had missing data on HBV viral loads (n = 8) or missing data on BCP or pc genetic variability (n = 82). In total, 86 patients were included in analysis. Demographic, HIV-related and HBV-related characteristics at baseline are summarized in Table 1 .
These characteristics are compared between source studies in Table   S2 , demonstrating a significantly lower CD4+ T-cell count (P < .001) and higher proportion with WHO clinical stage III/IV (P = .007) among participants enrolled in the Trivacan vs Temprano study. Table 2 describes specific BCP and pc mutations identified at baseline. The most common mutations were A1850T and C1858T nt substitutions on the pc region. Roughly two-thirds of patients (59.3%) harboured the G1896A or mixed G1896G/A pc mutation and almost one-quarter of patients harboured the A1762T (21.2%) or G1764A (24.7%) BCP mutations. Almost all patients with a BCP mutation at these nt positions also had the pcG1896A mutation (n = 19/21, 90.5%).
| Basal core promoter/precore mutant variants at baseline
As shown in Table 3 , the pcG1896A mutation at baseline was associated with HBeAg-negative status (P < .001), anti-HBe positive status (P < .001), lower HBV-DNA levels (P = .001) and presence of BCP mutations (P = .004). Of note, median ALT/AST levels were not significantly different in patients with vs without the pcG1896A mutation (32/39 IU/mL vs 25/40 IU/mL, respectively, P = .10/.6). Only two patients harboured a genotype other than E (genotype A) in whom no pcG1896A mutation was detected. In multivariable analysis, HBeAg-negative status (P < .001) and the presence of BCP mutations (P < .001) were significantly and independently associated with baseline presence of pcG1896A mutations (Table 3) , while considering the strong co-linearity between associated variables. BCP, basal core promoter; HBeAg, hepatitis B "e" antigen; PC, precore.
(IQR = 11-23) months of follow-up (cumulative proportion = 78.9%).
Time to undetectable HBV-DNA was significantly faster for patients with vs without baseline pcG1896A (cumulative proportion = 86.6% vs 66.9%, respectively, log-rank test P = .04) ( Figure 1B ). However, this association was no longer significant after adjusting for baseline HBV-DNA levels and anti-HBV agent (P = .2). At the end of follow-up, 31 (36.1%) patients had detectable HBV-DNA, with no significant difference between mutation groups (with pcG1896A = 31.4% vs without pcG1896A = 42.9%, P = .3). Thirteen (41.9%) of these patients had an HBV-DNA viral load >10 000 copies/mL, only one of whom developed the LAM resistance rtV173L+rtL180M+rtM204V mutation during treatment (without the pcG1896A mutation at baseline). the end of follow-up. At baseline, qHBeAg levels were lower in patients with vs without the pcG1896A mutation (24.9 PEI U/mL, n = 7 vs 164.6 PEI U/mL, n = 27, respectively), yet this association was not significant (P = .13). No significant differences between mutation groups were observed in change of qHBeAg levels from baseline (P = .9), owing to the low antigen levels overall during anti-HBV treatment (Figure 2A ). HBeAg-seroclearance occurred in 18 patients after a median 12 months (IQR = 11-23) of follow-up (cumulative proportion = 55.3%), with no significant difference in time to HBeAg-seroclearance between patients with vs without the pcG1896A mutation (cumulative proportion = 57.1% vs 54.3%, respectively, P = .7) ( Figure 2B ).
| Lack
Overall, median qHBsAg levels decreased from 4.00 log 10 IU/ mL (IQR = 3.36-4.36) at treatment initiation to 3.79 log 10 IU/mL (IQR = 3.10-4.15) at the end of follow-up. qHBsAg levels at baseline were significantly lower in patients with vs without the pcG1896A mutation (3.81 vs 4.24 log 10 IU/mL, respectively, P = .02). Over time, change in qHBsAg levels from baseline was significantly faster in patients without the pcG1896A mutation (P < .001) with substantial TA B L E 3 Determinants of precore G1896A mutation at baseline between-patient variability ( Figure 2C ). HBsAg seroclearance occurred in 12 patients after a median 12 months (IQR = 12-21) of follow-up (cumulative proportion = 14.5%). Baseline and 12-month characteristics of patients are compared between those with vs without HBsAg seroclearance in Table 4 . Ten and two of these patients were HBeAgpositive and HBeAg-negative, respectively, with HBeAg-positive patients more likely to lose HBsAg (log-rank test P = .001). As shown in Figure 2D , only patients without the pcG1896A mutation exhibited F I G U R E 1 HBV-DNA viral loads during treatment and precore G1896A mutation. HBV-DNA viral loads (A) and cumulative probability of achieving undetectable HBV-DNA viral load (B) are compared between patients with and without the precore G1896A mutation at treatment initiation. Individual levels of HBV-DNA are expressed as grey lines, whereas median levels are given as dots. HBV-DNA was imputed at detection thresholds (12 copies/mL) when undetectable F I G U R E 2 Hepatitis B virus (HBV) serological parameters during treatment and precore G1896A mutation. The following end-points were compared between patients harbouring the precore G1896A mutation at treatment initiation: (A) hepatitis B "e" antigen quantification (qHBeAg), (B) cumulative probability of HBeAg seroclearance for patients with HBeAg-positive serology at baseline, (C) hepatitis B surface antigen quantification (qHBsAg), and (D) cumulative probability of HBsAg seroclearance. Individual levels of qHBeAg and qHBsAg are expressed as grey lines, whereas median levels are given as dots. Levels of these markers were imputed at detection thresholds (0.05 IU/mL or PEI U/mL) when their corresponding serological result was negative HBsAg seroclearance (P < .001). This significant association held when adjusting for baseline qHBsAg levels and anti-HBV treatment regimen (P < .001).
| Low incidence of pcG1896A mutation during treatment
Of the 35 patients without the pcG1896A mutation at baseline, two patients developed incident pcG1896A mutations during treatment (IR = 2.5/100 person-years). The first patient had high HBV-DNA levels at treatment initiation (7.57 log 10 copies/mL). The patient was undergoing LAM-containing ART with CD4+ T-cell guided therapeutic interruptions. The G1896G/A mutation was detected at the month-24 visit with an HBV-DNA viral load at 228 000 copies/ mL, which gradually declined to 9260 copies/mL at the last study visit. The patient remained HBeAg-positive and HBsAg-positive during follow-up. The second patient also had high HBV-DNA at treatment initiation (7.93 log 10 copies/mL). After initiating continuous 
TA B L E 4 Determinants of HBsAg seroclearance
LAM-containing ART, HBV-DNA viral loads steadily decreased to 1074 copies/mL at month-24, when the G1896G/A mutation was detected, and finally to 810 copies/mL at the last study visit. The patient lost both HBeAg and HBsAg during follow-up, while no apparent mutations on the "a" determinant of the S-gene emerged.
No LAM-resistance mutations were observed for either patient.
| D ISCUSS I ON
The pcG1896A mutation is frequently observed around the time of HBeAg seroconversion, allowing abrogated HBeAg production with persistent HBV-DNA replication and possibly immune escape from HBeAg-directed immune responses. 23 As most patients in Western
Africa are HBeAg negative and infected with HBV genotypes prone to the G1896A nt substitution, 24, 25 it is assumed that a substantial proportion with detectable HBV-DNA replication would be infected with this mutation.
At treatment initiation, we did indeed identify pcG1896A mutant variants in almost two-thirds of co-infected patients harbouring genotype E, reflecting other studies in this region. [26] [27] [28] The presence of this mutation was associated with widely recognized determinants of more inactive forms of HBV infection, such as low HBV-DNA replication and HBeAg-negative status. As the G to A substitution at position pc1896 replaces tryptophan for a stop codon during translation of the HBeAg and thereby limits its production, 23 it is unsurprising that this mutation was not frequently observed in HBeAgpositive individuals. BCP mutations at either nt 1762 or 1764 were almost always present with the pcG1896A mutation in our study and are also associated with reduced HBeAg production and HBeAgnegative status. 29 Meanwhile, CD4+ T-cell concentrations failed to
show an association with baseline pc mutation and would suggest that HIV-induced immunosuppression might not play an essential role on the genetic variability of the pc region.
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We further our understanding on the therapeutic role of the pcG1896A mutation in genotype E infection, while clearly demonstrating that patients with this mutation at treatment initiation will likely have difficulty in clearing HBsAg during NA-based therapy.
Reduced HBsAg seroclearance rates have been described with this mutation, as well as with increased genetic diversity of the pc encoding region, during TDF treatment in HBV mono-infected patients. 11 The importance of this mutation was further evidenced when deep sequencing was applied, in which pcG1896A mutant strains detected as even minority variants (>1% of the HBV quasispecies pool) were able to produce greater sensitivity in predicting HBsAg seroclearance. 
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When replacing HBeAg-positive status with the lack of pcG1896A mutation, we were able to obtain a marginally higher sensitivity associated with loss of HBsAg in our study. Two HBeAg-negative individuals had HBsAg seroclearance, both of whom did not harbour the pcG1896A mutation. From our data, it is difficult to determine whether these individuals recently had HBeAg seroclearance prior to study inclusion or if the pcG1896A was present as a minority quasispecies. As increased pc genetic diversity during HBeAg seroconversion spans over several years, 34 perhaps the presence of pc mutations might be a more accurate reflection of later stages of HBV infection when HBsAg seroclearance is most difficult to clear.
Whether this means that earlier treatment prior to pc mutant emergence should be considered remains to be determined.
Patients harbouring the pcG1896A mutation at baseline did not have increased rates of HBeAg seroclearance, which was somewhat unexpected. 8 One reason could be the few patients with HBeAgpositive serology harbouring this mutation at baseline, thereby reducing the power to establish any difference. On the other hand, qHBeAg production did seem to persist for some patients with the pc mutation. It could be speculated that the quasispecies make-up of pcG1896A mutant variants remained at consistent levels during follow-up. Substantial evolutionary changes on the pc encoding region over time are needed in order for HBeAg seroconversion to occur, at least during the natural history of infection, 34 which might not have been the case in our study. This might also explain why there was no significant association with this mutation and qHBeAg at treatment initiation and during treatment, despite the well-established impact that the pcG1896A mutation has on HBeAg production in clinical settings. 35, 36 This hypothesis could be further clarified by examining the specific viral subpopulations during treatment using next-generation sequencing technologies.
We did not observe any association with the pcG1896A mutation at baseline and virological response or LAM resistance, which is in contrast to other studies evaluating the use of NA-based agents in HBV mono-infected patients. 8, 10 Several noteworthy features of our cohort could explain this finding. Persistent viraemia observed in these patients was mostly due to insufficient follow-up, immunocompromised status, or for some, LAM interruption. 17 TDF is also highly effective in suppressing HBV-DNA among co-infected patients, even when pcG1896A mutations are present. 37 These factors would have eclipsed any purported role of pcG1896A mutations on HBV suppression. In addition, HBV-DNA viral loads and transaminase levels were for the most part low at treatment initiation. These conditions might have been ideal to abate the emergence of LAM resistance 38 and have appeared to be associated with low LAM resistance rates in other treated, co-infected populations from SSA.
39
Considering that only one patient in this study had LAM resistance, there was an insufficient number of events to appropriately address this question.
As previously shown in treated co-infected patients, 40 the pcG1896A mutation emerged infrequently during follow-up. It is debatable, however, whether this pc mutation was truly incident.
Appearance of the G1896A nt substitution did not occur in concert with ALT increases, which is a common event in HBeAg seroconversion when genetic alterations on the pc region are readily observed. 34, 41 Furthermore, mixed wild type and pcG1896A was observed in the two patients identified with incident mutation. These patients potentially had minority variants at treatment initiation and Other limitations of our study need to be addressed. First, we excluded patients with severely elevated transaminases or clinical signs of severe liver disease at study inclusion. This criterion probably resulted in the lack of liver-related clinical events observed during follow-up and thus the relationship between BCP or pc mutations and liver-related morbidity was unable to be assessed. Conversely, individuals with occult HBV infection, which is rather prevalent in SSA, 16 were not included in our study. Although the low levels of HBV-DNA often observed in these patients make it difficult to conduct sequencing, the few reports of occult infection in SSA do not support high prevalence of the pcA1896G mutations during this infection "phase". hence, this scenario would be considered fairly unlikely.
Another consideration worth mentioning is the higher rate of HBeAg seroclearance and HBsAg seroclearance from what would be expected among treated HBV mono-infected patients. 33 Other studies in European and Asian co-infected cohorts have observed this phenomenon, which has been linked to accelerated ARTinduced immunorestoration under severe immunosuppression. 45, 46 Individuals with vs without HBsAg seroclearance did have somewhat lower CD4 T-cell count at baseline; yet, the lack of difference in ontreatment CD4 increases would suggest that immunocompromised status might not explain most of the seroclearance events observed in our study.
In conclusion, the lack of pcG1896A mutation at baseline, as determined by population sequencing, was strongly linked to HBsAg seroclearance in this group of NA-treated co-infected patients.
However, rates of HBeAg-seroclearance and virological response were no different between patients with or without this pc mutation. In the light of these findings, there could be a strong rationale to initiate NA-based therapy in HBV-infected patients from this setting before the pcG1896A mutation emerges. Nevertheless, future research would be needed to investigate the genetic diversity of the pc and BCP encoding regions of these strains and confirm its therapeutic and clinical utility.
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